By Mary Stuart
Published in the March 16, 2016 Issue (Vol. 3, No. 4)
– Who Will Pay for Wearables?
– Drug Compliance: A Wearable Device Improves Drug Efficacy with Patient-Specific Timing and Support
– A Digital Biomarker Helps Hospitals Treat Post-Op Patients
– Cardiovascular Monitoring: The Power of Continuous Data
– Epilepsy: Predictive Capabilities Save Lives, Empower Patients
Healthcare is moving towards a value based payment system, which, in theory, should reward wearable technologies that can measure, coach, and teach patients to keep them healthy and out of the highest cost care settings. But investors and many medical device companies themselves remain skeptical as to the clinical value of wearables, and it is far from clear how they can get paid for their investments in wearable medtech. Some early movers believe they can overcome the burden of proof.
Biotricity Inc.—Chrono Therapeutics Inc.—Emfit Ltd.—Empatica Inc.—GI Logic LLC—Gilead Sciences Inc.—G-Tech Medical Inc.—Google—Intel Corp.—iRhythm Technologies Inc.—Massachusetts Institute of Technology—Medtronic plc—NeuroMetrix Inc.—NIESM Pty Ltd.—Philips Healthcare—Otsuka Pharmaceutical Co. Ltd.—Proteus Digital Health—ResMed Inc.—SmartMonitor—Verily